Drug Profile
PF 3716539
Alternative Names: PF-03716539; PF-3716539Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator ViiV Healthcare
- Developer Pfizer
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Viral-infections(In volunteers) in Belgium (PO)
- 01 Oct 2008 Phase-I clinical trials in healthy volunteers in Belgium (PO)